iRadimed (NASDAQ:IRMD) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

iRadimed (NASDAQ:IRMD) posted its earnings results on Friday. The medical equipment provider reported $0.49 EPS for the quarter, topping the consensus estimate of $0.46 by $0.03, FiscalAI reports. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The business had revenue of $21.98 million during the quarter, compared to the consensus estimate of $21.32 million. iRadimed updated its FY 2026 guidance to 2.060-2.210 EPS and its Q2 2026 guidance to 0.440-0.480 EPS.

Here are the key takeaways from iRadimed’s conference call:

• Record quarter and raised guidance: Q2 revenue was $20.4M (+14% YoY) with 78% gross margin and GAAP diluted EPS of $0.45 (+18% YoY); management raised FY2025 revenue guidance to $80.0–$82.5M, raised EPS ranges, and declared a $0.17 quarterly dividend.
• FDA clearance of the MRidium 3870: Management calls the clearance a “seminal” event and expects the new pump (≈12% higher ASP) to unlock large replacement demand from >6,200 U.S. 5+-year-old channels, targeting an eventual domestic pump device revenue lift toward ~$50M in 2026.
• Backlog and commercial cadence: The company reports a record backlog (pump backlog ~5–6 months, monitor backlog ~4–5 weeks) and plans a controlled rollout—limiting broad selling of the 3870 through year‑end—so pump bookings may be muted initially even while revenue is supported by backlog.
• Near-term headwinds and international softness: International revenue declined 9% (domestic now ~89% of sales), the facility move will cause short-lived operational inefficiencies, and ongoing capex (final facility payments) could pressure near-term free cash flow and operating expenses.

iRadimed Price Performance

NASDAQ:IRMD traded up $3.71 during trading hours on Friday, reaching $87.15. 346,336 shares of the company were exchanged, compared to its average volume of 103,465. The business has a 50 day moving average of $96.69 and a 200 day moving average of $93.87. The company has a market capitalization of $1.11 billion, a P/E ratio of 49.80 and a beta of 1.11. iRadimed has a 1-year low of $50.31 and a 1-year high of $107.90.

iRadimed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s dividend payout ratio is currently 45.71%.

Insider Buying and Selling at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 3,750 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $89.16, for a total value of $334,350.00. Following the sale, the chief executive officer owned 2,198,750 shares of the company’s stock, valued at approximately $196,040,550. This trade represents a 0.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 48,750 shares of company stock valued at $4,708,950. Company insiders own 36.80% of the company’s stock.

Institutional Investors Weigh In On iRadimed

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of iRadimed by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock valued at $40,313,000 after purchasing an additional 5,475 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of iRadimed by 410.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after buying an additional 205,783 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of iRadimed by 1.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 217,129 shares of the medical equipment provider’s stock worth $21,123,000 after buying an additional 2,578 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of iRadimed by 37.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock worth $19,964,000 after buying an additional 55,426 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of iRadimed by 3.1% during the fourth quarter. State Street Corp now owns 192,952 shares of the medical equipment provider’s stock worth $18,770,000 after buying an additional 5,713 shares in the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Roth Mkm restated a “buy” rating and set a $120.00 target price on shares of iRadimed in a research report on Tuesday, February 10th. Freedom Capital raised iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Finally, Lake Street Capital reaffirmed a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $120.00.

iRadimed News Summary

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Q1 earnings and revenue beat consensus: iRadimed reported non‑GAAP EPS of $0.49 (GAAP $0.45) and revenue of ~$22.0M, both above expectations, with year‑over‑year EPS and revenue growth — a primary driver of the intraday rally. iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Record GAAP and improved margins: management highlighted record GAAP diluted EPS and improved net margin/ROE metrics, signaling operating leverage and pricing/volume strength. IRADIMED Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dividend increase maintained: the company announced a regular quarterly cash dividend of $0.20 (up from $0.17), which supports income-oriented investors and signals confidence in cash flow. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Full‑year guidance reaffirmed and nudged slightly above consensus: FY2026 EPS guidance was set to $2.06–$2.21 (consensus ~2.05), and revenue guidance roughly $91–96M (consensus ~$92.4M) — supportive but not a major beat. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: CEO insider sale disclosed: CEO Roger Susi sold 3,750 shares under a pre‑arranged Rule 10b5‑1 plan — a small, orderly sale that management says was planned, so likely neutral for most investors. Insider Selling: iRadimed CEO Sells Shares
• Negative Sentiment: Q2 revenue and mid‑point EPS guidance slightly cautious vs. street: Q2 revenue guidance of $20.0–$21.0M is modestly below consensus (~$21.1M) and Q2 EPS guidance (0.44–0.48) straddles the street estimate — this introduces short‑term execution risk that could temper gains. IRADIMED Reports First Quarter 2026 Financial Results

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.